|
LYPLA1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.6718000024093E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.81389999979132E-08 |
| Normal-vs-Stage2 |
2.468100E-02 |
| Normal-vs-Stage3 |
3.20429999978167E-07 |
| Normal-vs-Stage4 |
1.53690005166851E-09 |
| Stage1-vs-Stage2 |
2.000600E-01 |
| Stage1-vs-Stage3 |
2.949000E-01 |
| Stage1-vs-Stage4 |
7.539600E-03 |
| Stage2-vs-Stage3 |
6.407600E-02 |
| Stage2-vs-Stage4 |
6.062800E-03 |
| Stage3-vs-Stage4 |
1.274200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.09040004697891E-09 |
| Normal-vs-AfricanAmerican |
1.55936999999273E-05 |
| Normal-vs-Asian |
3.39429999995922E-07 |
| Caucasian-vs-AfricanAmerican |
4.119400E-01 |
| Caucasian-vs-Asian |
4.680400E-01 |
| AfricanAmerican-vs-Asian |
8.097800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.09509999957069E-08 |
| Normal-vs-Female |
4.34199999954643E-07 |
| Male-vs-Female |
1.303160E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.80660000004274E-06 |
| Normal-vs-Age(41-60Yrs) |
2.06329997531896E-09 |
| Normal-vs-Age(61-80Yrs) |
1.67760999999489E-05 |
| Normal-vs-Age(81-100Yrs) |
5.906100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.741800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.500000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.260800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.331570E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.229200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.103200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.751800E-01 |
| Classical-VS-Follicular |
1.203660E-02 |
| Classical-VS-Other |
2.090600E-01 |
| Classical-VS-Normal |
7.30570048901313E-10 |
| Tall-VS-Follicular |
1.480000E-01 |
| Tall-VS-Other |
3.477600E-01 |
| Tall-VS-Normal |
2.449400E-04 |
| Follicular-VS-Other |
9.951700E-02 |
| Follicular-VS-Normal |
1.276400E-02 |
| Other-VS-Normal |
3.412100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.15150000049525E-07 |
| Normal-vs-N1 |
9.55910017808037E-10 |
| N0-vs-N1 |
4.211600E-02 |
|
|
